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Summary
BACKGROUND AND AIMS: Cardiovascular diseases
(CVD) increase late morbidity and mortality in survivors of
acute lymphoblastic leukaemia (ALL). We compared the
risk of CVD in ALL survivors to siblings, examined time
trends, quantified treatment-related risks, and investigated
whether risk extends beyond patients treated with anthra-
cyclines and chest radiotherapy.
METHODS: The Swiss Childhood Cancer Survivor Study
assessed CVD by patient questionnaire in 5-year ALL sur-
vivors diagnosed between 1976 and 2005 and their sib-
lings. Participants were asked whether a physician had
ever told them that they had hypertension, arrhythmia,
heart failure, myocardial infarction, angina pectoris,
stroke, thrombosis or valvular problems. We investigated
treatment-related risk factors for CVD using multivariable
logistic regression, adjusting for demographic and socioe-
conomic factors, BMI, smoking, diabetes mellitus, alcohol
consumption and physical activity.
RESULTS: We contacted 707 survivors and 1299 siblings,
511 (72%) and 709 (55%) of whom responded, respec-
tively. Survivors had a higher risk of developing CVD than
siblings (odds ratio [OR] 1.9, 95% confidence interval
1.3–2.8), in particular heart failure (OR 13.9, 1.8–107.4).
Compared to patients treated 1976–85, the risk of CVD
was 1.4 (0.7–2.8) for those treated 1985–1994 and 1.5
(0.6–3.7) for those treated 1995–2005. The overall CVD
risks after anthracycline treatment (OR 3.1, 2.0–4.7),
haematopoietic stem cell transplantation (OR 8.0,
2.4–26.9) or relapse (OR 4.1, 1.9–8.8) were increased
compared to those of siblings, while the CVD risks of sur-
vivors treated without anthracycline or chest radiotherapy
were similar (OR 1.0; 0.5–2.0).
CONCLUSIONS: Despite attempts to reduce cardiotoxic-
ity in childhood cancer treatment, CVD risks in ALL sur-
vivors treated more recently do not seem to have declined.
Trial registration number: NCT03297034
Keywords: cardiovascular, late effects, leukaemia, car-
diotoxic, heart failure, anthracycline, Swiss Childhood
Cancer Registry, Europe
Introduction
Acute lymphoblastic leukaemia (ALL) is the most com-
mon malignancy in childhood. Its incidence has increased
in recent decades [1]. Better treatments have improved
five-year survival rates to 85 percent [1, 2]. A consequence
of these effective treatments is damage to normal tissues,
which may result in the long-term dysfunction of many or-
gans. The cardiovascular system is particularly vulnerable
to cancer treatment, and cardiovascular diseases (CVD) are
recognised late effects of cancer treatment [3]. Survivors
of childhood ALL have a lifelong increased risk for cardio-
vascular morbidity and mortality compared to the general
population, mainly caused by chemotherapy with anthra-
cyclines or, to a lesser extent, by direct or scattered chest
radiotherapy [4]. ALL survivors also have an increased
prevalence of insulin resistance and dyslipidaemia [5], and
differ from their siblings in health behaviours relevant for
CVD, such as physical activity, smoking and alcohol con-
sumption [6–9].
In recent decades, cumulative doses of potentially car-
diotoxic treatments for ALL have been reduced. Today,
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low-risk patients receive lower anthracycline doses, and
craniospinal radiotherapy is only given to children who re-
lapse [3, 10]. A recent American study reported a reduction
of cardiac mortality among ALL survivors [10], but there
are no studies of time trends in non-lethal cardiovascular
late effects after childhood cancer. Previous studies of car-
diovascular morbidity were mostly restricted to survivors
diagnosed before 1990, who were treated with protocols
that are no longer in use [4, 11–14]. More recent work has
suggested that cardiovascular risk may extend beyond sur-
vivors who had anthracyclines or chest radiotherapy [15].
Follow-up care after the end of treatment has been intensi-
fied and now includes screening for early CVD.
In the Swiss Childhood Cancer Survivor Study (SCCSS),
we assessed physician-diagnosed CVD with patient ques-
tionnaires. This study compares the risk of CVD reported
by ALL survivors to that of their siblings, and changes in
risk based on the calendar period of diagnosis. It also ex-
amines treatment-related risk factors for CVD in order to
determine whether risk increases are confined to patients
exposed to cardiotoxic anthracyclines and chest radiother-
apy.
Material and methods
Study population
The SCCSS is a population-based, long-term follow-up
study of all childhood cancer patients registered in the
Swiss Childhood Cancer Registry (SCCR) who have sur-
vived for at least five years after cancer diagnosis. Children
in the study were diagnosed between 1976 and 2005 and
before the age of 20 with leukaemia, lymphoma, central
nervous system tumours, malignant solid tumours or
Langerhans cell histiocytosis [16]. Between 2007 and
2012, we sent questionnaires (in German, French or Ital-
ian) to all survivors. The questionnaire is based on those
used in American and British childhood cancer survivor
(CCS) studies [17, 18]. It assessed quality of life, health
outcomes, current medication and health service use, psy-
chological distress, health behaviour and socioeconomic
information. This study includes only participants who
were diagnosed with ALL before age 16 years, had sur-
vived more than five years after diagnosis, and were 16
years or older and alive at the time of the survey. Those
who did not respond to the first mailing received a second
copy of the questionnaire. If they again did not respond,
we contacted them by phone. Siblings were contacted as a
control group. If survivors agreed, we sent a similar ques-
tionnaire without cancer-related questions to their siblings.
More detailed information on the study design has been
published elsewhere [19].
Ethics approval was granted by the Ethics Committee of
the Canton of Bern to the SCCR and SCCSS (KEK-BE:
166/2014) and the SCCSS is registered at ClinicalTri-
als.gov (identifier: NCT03297034).
We reported the results according to the STROBE guide-
lines [20].
Cardiovascular outcomes
The questionnaire included a separate section on CVD, as
in the American and British CCS studies (see figure S1
in appendix 1) [17, 18]. We asked survivors and siblings
whether they had ever been diagnosed with arterial hyper-
tension, arrhythmia, heart failure or cardiac dysfunction,
myocardial infarction, angina pectoris, stroke, deep vein
thrombosis or pulmonary embolism, or valvular problems.
Arteriosclerosis, though mentioned in the questionnaire,
was not analysed as CVD. Reporting at least one CVD was
the primary outcome for the analysis. Respondents could
use a free text field to describe additional CVD, including
pericarditis. Two authors, CEK and JNC, independently re-
coded all problems mentioned in the free text fields into
the CVD categories mentioned and resolved any discrep-
ancies. We coded missing data in outcomes as “no” based
on the assumption that people who did not tick “yes” did
not have a clinically relevant disease.
Explanatory variables
We obtained detailed information on sociodemographic
characteristics, diagnoses and treatments from the SCCR
(see appendix 2). These included gender, nationality, can-
cer diagnosis, year and age at cancer diagnosis, age at sur-
vey, chemotherapy, clinical study participation, treatment
protocol, radiotherapy, surgery, haematopoietic stem cell
transplantation (HSCT) and history of relapse. Information
on follow-up, sociodemographic and behavioural cardio-
vascular risk factors came from the SCCSS questionnaire.
Statistical analysis
For better comparison to survivors, we weighted the sib-
ling responses for all analyses according to age, gender,
language region and migration background, as previously
described [8, 21] (supplementary table S1 in appendix 3).
First (analysis 1), we compared the prevalence of CVD re-
ported by ALL survivors and siblings using standardised
χ2 tests. We calculated odds ratios and their 95% con-
fidence intervals (CI) for each outcome, comparing sur-
vivors to siblings using weighted univariable logistic re-
gressions.
We then investigated the effects of cancer related variables
on our main outcome (≥1 CVD), again using weighted lo-
gistic regressions. In the first of these analyses (analysis
2), we investigated whether CVD risks among survivors
differed by period of cancer diagnosis (1976–1984,
1985–1994, 1995–2005). This regression model was fur-
ther adjusted for participation in follow-up care in order to
examine any potential effects of detection or recall bias.
Survivors attending follow-up care might have been better
and/or more recently screened for cardiac problems and
therefore report more CVD.
Next (analysis 3), we investigated differences in CVD risk
according to treatment-related risk factors (cancer diagno-
sis, age at diagnosis, history of relapse, chemotherapy, ra-
diotherapy, haematopoietic stem cell transplantation, fol-
low-up care and the different cardiotoxic treatment
combinations described above). This analysis included
both survivors and siblings (reference group).
Regression models of analyses 2 and 3 were adjusted for
recognised cardiovascular risk factors (age, gender, migra-
tion background, language region, parents’ highest educa-
tion, BMI, smoking status, diabetes mellitus, alcohol con-
sumption and physical activity). Given this large number
of covariates, we followed an approach proposed by Ar-
bogast et al. and Miettinen to reduce dimensionality [22,
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23]. In this approach, adjustment for multiple cardiovascu-
lar risk factors is done using a summary disease risk score
(DRS). To generate the DRS, the outcome is regressed on
all the potential confounders and exposures of interest. The
results from this intermediate regression are shown in table
S2 (appendix 3). For each participant and for each expo-
sure of interest, the DRS was calculated as the log odds of
the outcome predicted from this fitted model while treating
the individual as unexposed. In the same way, a DRS was
calculated for each participant by treating the individual as
simultaneously unexposed to all exposures of interest.
All analyses were performed using the statistical software
package Stata (Version 13, Stata Corporation, Austin,
Texas).
Results
Characteristics of ALL survivors and siblings
We included responses from 511 of the 707 ALL survivors
whom we contacted (response rate 72%), and 709 of 1,299
siblings (55%, fig. S2 in appendix 3) in the analysis.
Fifty percent (n = 258) of the 511 ALL survivors were
male. Twenty-six percent of survivors were aged 16–20,
49% 21–30, and 25% over 30 at the time of the survey.
Cardiovascular risk factors differed between ALL sur-
vivors and siblings: ALL survivors had more diabetes mel-
litus, consumed less alcohol and were less physically ac-
tive (table S1 in appendix 3). Responders were more often
between 21 and 30 years old at survey, female, and diag-
nosed in earlier time periods than nonresponders. They did
not differ by history of relapse or cancer treatment (table
S3).
Cardiotoxic treatment has changed in recent decades (table
1). All ALL survivors had received chemotherapy, includ-
ing 62% (315/511) with anthracyclines. Anthracycline use
increased from 42% in 1976–1984, to 71% in 1985–1994,
and decreased again to 63% in those diagnosed
1995–2005. Overall, 30% (151/511) of survivors received
radiotherapy, and 5% (23/511) radiotherapy to the chest.
This last proportion decreased from 9% in 1976–1984 to
4% in 1985–1994 and 1% in 1995–2005. HSCT was per-
formed in 5% (23/511) of all survivors, with no significant
change over time.
Risk of CVD in ALL survivors
Compared to siblings, ALL survivors had an increased risk
of CVD. Fourteen percent of 511 ALL survivors reported
at least one CVD compared to 8% of siblings (OR 1.9, 95%
CI 1.3–2.8; p = 0.002) (table 2). Evidence of an increased
risk among survivors was strongest for cardiac problems
(OR 2.3, CI 1.4–3.8), especially high for heart failure (OR
13.9, CI 1.8–107.4).
We found no evidence for a time trend in self-reported
CVD (fig. 1). As figure 1 illustrates, compared to survivors
diagnosed 1976–84, the relative odds of CVD were 1.4
(0.7–2.8) for those diagnosed 1985–94 and 1.5 (0.6–3.7)
for those diagnosed 1995–2005 (p = 0.567, Model A).
Odds ratios remained qualitatively similar when we ad-
justed for the attendance of follow-up care (Model B): 1.3
(0.7–2.6) for those diagnosed 1985–1994 and 1.1 (0.4–2.9)
for those diagnosed 1995–2005.
Treatment-related risk factors for CVD
Adjusting for the baseline DRS, we found increased risks
for developing CVD compared to siblings in ALL sur-
vivors treated recently (OR 4.1, CI 2.1–7.9), with a history
of relapse (OR 4.1, CI 1.9–8.8), those treated with anthra-
Table 1: Treatment related characteristics of acute lymphoblastic leukaemia survivors by calendar period of diagnosis.
ALL Survivors (n = 511) 1976–1984
(n = 135)
1985–1994
(n = 245)
1995–2005
(n = 131)
p-value*
n (%) n (%) n (%)
Age at questionnaire (years) 16–20 0 0 47 19 88 67 <0.001
21–30 36 27 172 70 43 33
31–40 81 60 26 11 0 0
41 or more 18 13 0 0 0 0
Age at diagnosis (years) 0–4 69 51 140 57 35 27 <0.001
5–9 48 36 66 27 41 31
10 or more 18 13 39 16 55 42
History of relapse Yes 29 22 26 11 15 11 0.009
Chemotherapy Other CT† 78 58 70 29 48 36 <0.001
Anthracycline 57 42 175 71 83 63
Radiotherapy No RT 73 53 185 76 103 79 <0.001
Other RT‡ 52 39 49 20 27 21
Chest RT§ <20 Gy 7 5 7 3 0 0
Chest RT§ 20–39 Gy 5 3 4 2 1 1
HSCT Allogeneic 6 4 7 3 6 5 0.301
Autologous 0 0 3 1 1 1
Combination of therapies¶ Other CT†, no or other RT‡ 77 57 69 28 48 37 <0.001
Anthracyclines, no or other RT‡ 46 34 165 67 82 63
Anthracyclines, chest RT§ 11 8 10 4 1 1
Still in follow-up care‖ Yes 14 11 44 19 77 63 <0.001
ALL = acute lymphoblastic leukaemia; CT = chemotherapy; HSCT = haematopoietic stem cell transplantation; RT = radiotherapy Percentages are based upon available data for
each variable. * p-values from chi-squared tests comparing the different time periods † Other chemotherapeutic agents: any chemotherapy other than anthracycline (n = 165) and
those who received chemotherapy with unknown details (n = 31) ‡ Other radiotherapy: no history of radiotherapy on the chest (limbs, cranial, neck, pelvis and abdomen) § Chest
radiotherapy: mantle field, total body irradiation, thoracic spine radiation, unspecified radiation of the thorax ¶ Patients with HSCT are excluded ‖ Still in clinical follow-up care after
cancer treatment at the time of the study (for raw data, see table S4 in appendix 3).
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cyclines (OR 3.1, CI 2.0–4.7), and those who had a HSCT
(OR 8.0, CI 2.4–26.9) (table 3).
We observed an increased risk of CVD in those treated
with both anthracyclines and chest radiotherapy (OR 2.5,
CI 0.5–13.7) and in those treated with anthracyclines alone
(OR 2.8, CI 1.8–4.5) (fig. 2). ALL survivors treated with
chemotherapy other than anthracyclines had a risk similar
to that of their siblings (OR 1.0, CI 0.5–2.0).
Discussion
Swiss ALL survivors had a nearly two-fold greater risk for
CVD than siblings overall. Risk was most pronounced for
heart failure, and CVD risk did not decrease in survivors
treated more recently. Only patients treated with anthracy-
clines, radiotherapy to the chest or HSCT were at risk for
CVD, with little evidence of increased risks of other regi-
mens.
Drawing upon the national SCCSS, these results are repre-
sentative of all Swiss ALL survivors, conditional on being
5-year survivors and alive. Because our study had nation-
wide coverage, we believe our results are broadly general-
isable for ALL patients from developed countries. Patients
in Switzerland are treated according to international proto-
cols used in Europe and North America. Of particular rele-
vance is our inclusion of recently treated patients. A further
strength of this study is its systematic use of the disease
risk score, which allowed us to adjust for many cardiovas-
cular risk factors simultaneously to obtain more precise ef-
fect estimates [22].
The main limitation of the study is the low number of cas-
es, caused by the young age of participants. This leads to
Table 2: Prevalence* of self-reported cardiovascular disease in acute lymphoblastic leukaemia survivors compared with siblings.
ALL survivors
(n = 511)
Siblings†
(n = 709)
OR 95% CI p-value§
n %‡ n %‡
Any CVD¶ 73 14.3 58 8.1 1.9 1.3–2.8 0.002
Multiple (≥2) CVD 12 2.4 8 1.1 2.1 0.8–5.6 0.142
Cardiac problems only‖ 47 9.2 29 4.2 2.3 1.4–3.8 0.001
Hypertension** 24 4.7 26 3.8 1.3 0.7–2.4 0.438
Arrhythmia** 27 5.3 21 3.0 1.8 1.0–3.5 0.065
Heart failure or cardiomyopathy** 12 2.4 1 0.2 13.9 1.8–107.4 0.012
Myocardial infarction** 1 0.2 2 0.3 0.6 0.0–9.6 0.717
Angina pectoris** 8 1.6 8 1.2 1.4 0.5–3.9 0.512
Stroke** 3 0.6 1 0.2 3.8 0.6–24.2 0.163
Venous thrombosis/pulmonary embolism** 5 1.0 5 0.7 1.5 0.4–4.9 0.532
Valvular problems** 8 1.6 4 0.7 2.6 0.8–8.0 0.094
ALL = acute lymphoblastic leukaemia; CVD = cardiovascular diseases; CI = confidence interval; OR = odds ratio * Missing values coded to 0 † Siblings’ numbers and percentages
weighted for survivor characteristics (standardised for age, gender, migration background and language region) ‡ Column percentages are given § p-values calculated from logis-
tic regression models for weighted values comparing ALL survivors to siblings ¶ At least one of hypertension, arrhythmia, heart failure or cardiomyopathy, myocardial infarction,
angina pectoris, stroke, venous thrombosis/pulmonary embolism or valvular problems ‖ Hypertension, thrombotic problems and strokes excluded ** Missing values for outcome
(survivors, siblings): hypertension (1.1%, 5.1%), arrhythmia (1.1%, 4.7%), heart failure or cardiomyopathy (1.2%, 4.5%), myocardial infarction (1.4%, 4.3%), angina pectoris
(32.3%, 26.4%), stroke (1.9%, 4.5%), venous thrombosis / pulmonary embolism (1.7%, 4.5%), valvular problems (1.7%, 4.9%)
Table 3: Prevalence and relative odds for any cardiovascular disease in survivors of acute lymphoblastic leukaemia compared to siblings (OR 1.0) adjusted for the baseline risk
score.
No. total No. CVD %* CVD OR† 95% CI p-value‡
Diagnosis of ALL 511 73 14.3 2.2 1.5–3.4 <0.001
Period of cancer diagnosis 1976–1984 135 19 14.1 1.2 0.6–2.4 0.018
1985–1994 245 36 14.7 2.7 1.7–4.4
1995–2005 131 18 13.7 4.1 2.1–7.9
Age at diagnosis (years) 0–4 244 29 11.9 2.1 1.3–3.6 0.362
5–9 155 21 13.5 1.8 1.0–3.3
10 or more 112 23 20.5 3.0 1.6–5.6
History of relapse No 441 56 12.7 1.9 1.2–3.0 0.047
Yes 70 17 24.3 4.1 1.9–8.8
Chemotherapy Other chemotherapeutic agents§ 196 19 9.7 1.2 0.6–2.3 0.005
Anthracyclines 315 54 17.1 3.1 2.0–4.7
Radiotherapy No RT 359 48 13.4 2.3 1.5–3.6 0.645
Other RT¶ 128 21 16.4 2.0 1.0–3.9
Chest RT‖ 1–19 Gy 14 1 7.1 0.8 0.1–7.5
Chest RT‖ 20 or more Gy 10 3 30 8.5 1.4–51.6
HSCT** No 487 66 13.6 2.1 1.3–3.2 0.028
Yes 24 7 29.2 8.0 2.4–26.9
ALL=- acute lymphoblastic leukaemia; DRS=- disease risk score; CVD = cardiovascular diseases; HSCT = haematopoietic stem cell transplantation; OR = odds ratio; RT =
radiotherapy; CI = confidence interval Percentages are based upon available data for each variable. * Row percentages are given † Adjusted with Baseline DRS for age at
questionnaire, gender, migration background, language region, parents' education, smoking status, BMI, diabetes mellitus, alcohol consumption and physical activity ‡ P-values
calculated from Wald test for comparison within survivors only § Other chemotherapeutic agents: any chemotherapy other than anthracycline (n = 165) and those who received
chemotherapy with unknown details (n = 31) ¶ Other radiotherapy: no history of radiotherapy on the chest ‖ Chest radiotherapy: mantle field, total body irradiation, thoracic spine
radiation, unspecified radiation of the thorax ** Includes both autologous and allogeneic, and both peripheral blood cell and bone marrow transplantation
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large confidence intervals. A further limitation is that car-
diovascular conditions were self-reported without external
validation. Some participants could actually have hyper-
tension but not be aware of it because their blood pres-
sure has never been measured. As a sensitivity analysis,
we excluded ALL survivors who reported only hyperten-
sion from the analysis of risk factors. The directions and
strength of the associations did not change (period of can-
cer 1976–1984, OR 1.7, CI 0.7–3.7; 1985–1994, OR 2.9,
CI 1.7–5.1; 1995–2005, OR 3.9, CI 1.9–8.1). However, pe-
riod of cancer diagnosis was no longer significantly as-
sociated (p = 0.22) (see table S5 in appendix 3). We in-
terpret this as a lack of statistical power due to the lower
numbers of cardiac outcomes in the analysis. Although this
could lead to either under- or overestimation of CVD [24],
good agreement is possible between self-reported CVD
and medical records [25]. We did not include deceased cas-
Figure 1: Odds ratios for reporting a cardiovascular disease by
calendar period of diagnosis, adjusted for baseline risk (model A)
and for baseline risk and follow-up care (model B).* p-values cal-
culated from likelihood ratio tests.
Figure 2: Odds ratios and 95% confidence intervals for reporting
any cardiovascular disease in acute lymphoblastic leukaemia sur-
vivors by type of treatment. Results are adjusted for the baseline
disease risk score†.* p-values calculated from Wald test for survey
statistics comparing only inter-survivor responses; † Baseline dis-
ease risk score: adjusting for age at questionnaire, gender, migra-
tion background, language region, parents' education, smoking
status, body mass index, diabetes mellitus, alcohol consumption
and physical activity.Other CT: any chemotherapy other than an-
thracyclines and those who received chemotherapy with unknown
details; Chest RT: mantle field, total body irradiation, thoracic spine
radiation, unspecified radiation of the thorax.NOTE: Patients with
haematopoietic stem cell transplantation (n = 24) were excluded
from these analyses. There were no patients without chemothera-
py and only two patients with chest radiotherapy but no anthracy-
cline treatment.
es; however, few patients in our population died from a
cardiac cause [26]. We could not retrieve the anthracycline
status for 6% of the patients, and their treatment was clas-
sified as other chemotherapeutic agent. This might have in-
troduced bias, leading to an underestimation of the effect
of anthracyclines and an overestimation of the risk in those
exposed to other chemotherapy. We could not grade severi-
ty of CVD according to the Common Terminology Criteria
for Adverse Events (CTCAE) with the available informa-
tion [27].
Overall, the prevalence of CVD in our ALL-survivor co-
hort is similar to that reported from questionnaire surveys
in other childhood cancer survivors such as the assessment
of CVD in a large American childhood cancer survivor
study that used the same questions [12]. Respective preva-
lences in that study and ours were broadly comparable:
0.7% and 0.2% for myocardial infarction, 1.3% and 0.2%
for pericardial disease, 1.7% and 2.4% for cardiomyopa-
thy, and 1.6% and 1.6% for valvular diseases. Prevalence
of CVD in siblings was comparable in both. Hazard ratios
(odds ratios) for CVD, comparing ALL survivors with sib-
lings in this American (and our) study were 4.2 (13.9, 95%
CI 1.8–107.4) for congestive heart failure, 3.3 (0.6, 95%
CI 0.0–6.5) for myocardial infarction, and 2.6 (2.6, 95% CI
0.8–8.0) for pericardial disease and valvular abnormalities.
A Dutch study that assessed CVD during follow-up con-
sultations and by questionnaire reported a prevalence of
3.7% for cardiac events (congestive heart failure, cardiac
ischemia, valvular disease, cardiac arrhythmia, pericardi-
tis) in a population of 1,362 CCS with a median age of 29.1
years at study [14]. The reason why this prevalence is low-
er than our figure of 14.3% might be because the Dutch
study only included CVD with a CTCAE grade higher than
2, whereas we might also have included less severe mani-
festations. Both that study and ours contrast with a recent
study that assessed CVD by physical examinations and
echocardiography, which reported a prevalence of 7.4% for
cardiomyopathy, 3.8% for coronary artery disease, 28% for
valvular disease and 4.4% for conduction/rhythm disorders
[28]. However, only high-risk patients treated with anthra-
cyclines or chest radiotherapy were included in the study,
and subclinical disease was also detected by these exami-
nations.
Our study supports observations that HSCT and anthracy-
cline therapy are risk factors for CVD [3]. We found no
evidence suggesting that anthracycline and chest radiother-
apy have a synergistic effect, which is consistent with no
interaction between radiation dose and anthracycline expo-
sure in relation to cardiac deaths [29], although our study
was underpowered for assessing such interactions. Our re-
sults do not support the hypothesis that all cancer treat-
ments, in addition to anthracyclines and chest radiothera-
py, lead to an increased risk of CVD [28].
Over the past 20 years, anthracycline doses have been re-
duced in low-risk ALL patients, and craniospinal radio-
therapy is now limited to patients with relapse. The Amer-
ican childhood cancer survivor study reported a decrease
in the incidence of cardiac deaths from 0.6 in 1970–74 to
0.1 in 1990–1994 [10]. It is perhaps surprising, then, that
although cardiac mortality has declined, we observed no
relative reduction of risk for CVD in recently treated ALL
survivors compared to ALL survivors treated earlier. We
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offer two possible explanations for this finding. First, if
the incidence of CVD has remained constant while follow-
up care has improved, then we might detect CVD earlier
and offer better treatment options, and decreased cardiac
mortality ensues. Second, a small group of high-risk ALL-
patients has received even higher doses of anthracyclines.
Treatment of this small, high-risk group may have offset an
otherwise small decline to produce an incidence of CVD
that appears little changed. Engagement in more intense
follow-up may have led to the detection of more CVD in
recent years. In Model B (fig. 1), we adjusted for follow-up
care. However, we cannot fully rule out possible residual
confounding.
New studies should include clinical assessment of CVD
and more recently treated patients, and also assess both
morbidity in relation to mortality of CVD to avoid survivor
bias. In the clinic, closer, prospective follow-up of those
patients at risk may improve detection of subclinical CVD,
thus permitting earlier intervention that could reduce the
severity of outcomes.
Conclusion
Our national study of ALL survivors demonstrates the
higher risk of CVD in ALL survivors treated with known
cardiotoxic treatment regimens. Survivors treated with oth-
er regimens did not seem to have increased risk compared
to siblings. Despite attempts to reduce cardiotoxicity in
cancer treatment regimens during the past decades, we
found no decrease in CVD risk over time.
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Appendix 1
Questions on cardiovascular problems in the Swiss Childhood Cancer Survivor Study
The questions on cardiovascular problems in the Swiss Childhood Cancer Survivor Study are shown in figure S1.
Appendix 2: Explanatory variables from the Swiss Childhood Cancer Survivor Study (SCCSS)
We obtained detailed information on sociodemographic characteristics, diagnoses and treatments from the SCCR. These
included gender, nationality, cancer diagnosis, year and age at cancer diagnosis, age at survey, chemotherapy (yes/no),
clinical study participation (yes/no, study protocol, treatment arm), treatment protocol, radiotherapy (yes/no, area, dose),
surgery (yes/no, area, type), haematopoietic stem cell transplantation (yes, including autologous or allogeneic/no), and
history of relapse (yes/no). We determined anthracycline and other chemotherapeutic agent use (yes/no) through infor-
mation on clinical study participation and treatment protocol from the SCCR. Other chemotherapeutic agents included
any chemotherapy not containing anthracyclines and chemotherapy with unknown details. We classified radiotherapy into
four categories: No radiotherapy, Other radiotherapy, Chest radiotherapy 1-19 Gray (Gy) and Chest radiotherapy 20 Gy or
more. Chest radiotherapy included total body irradiation, mantle field irradiation or irradiation to the thorax, mediastinum,
or thoracic spine. Cardiotoxic treatment was divided into other chemotherapeutic agents and/or other radiotherapy, other
chemotherapeutic agents and chest radiotherapy, anthracyclines and other radiotherapy, and anthracyclines and chest ra-
diotherapy. We also categorised period of diagnosis (1976-84, 1985-94, ≥1995), age at diagnosis (0-4, 5-9, ≥10 years) and
age at questionnaire (16-20, 21-30, 31-40, or 41 or more years).
Information on follow-up, sociodemographic and behavioural cardiovascular risk factors came from the SCCSS question-
naire. We used data on parents’ highest education (primary, secondary, tertiary), migration background (yes/no), smoking
status (current/ever), height (cm) and weight (kg), diabetes mellitus (yes/no), alcohol consumption (Occasionally/never,
>=1 standard drink weekly, not daily, 1 standard drink daily and >1 standard drink daily) and physical activity (yes/no).
We asked survivors if they were still under regular follow-up care for their former childhood cancer (still in follow-up
care/not in follow-up care). We coded migration status as yes if a participant was born abroad, had no Swiss citizenship
at birth, or had at least one parent with no Swiss citizenship. We defined participants as physically active if they reported
being engaged in any fitness training or sports. We calculated the body mass index (BMI) for each participant (kg/m2) and
divided it into four categories: underweight, BMI <18; normal weight, BMI 18-24.9; overweight, BMI 25-30; and obese,
BMI >30.
Appendix 3: Supplementary data
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Figure S1: Questions on cardiovascular problems in the Swiss Childhood Cancer Survivor Study (German version)
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Figure S2: Study participants flow chart.* Not contacted because another sibling of the same family in the same age category was already
contacted.
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Table S1: Characteristics of acute lymphatic leukaemia survivors and siblings participating in the study.
ALL survivors
(n = 511)
Siblings
(n = 709)
Unweighted Weighteda
n (%b) n (%b) p-valuec (%b) p-valued
Sociodemographic conditions
Age at questionnaire (years)
‒ 16–20 135 (26.4) 120 (16.9) (27.6)
‒ 21–30 251 (49.1) 319 (45.0) (48.9)
‒ 31–40 107 (20.9) 195 (27.5) (20.0)
‒ 41 or more 18 (3.5) 75 (10.6) <0.001 (3.5) n.a.a
Gender
‒ Male 258 (50.5) 291 (41.0) (52.9)
‒ Female 253 (49.5) 418 (59.0) 0.001 (47.1) n.a.a
Migration backgrounde
‒ No migration background 466 (91.2) 679 (95.8) (76.7)
‒ Migration background 45 (8.8) 26 (4.2) <0.001 (23.3) n.a.a
Language region
‒ German 384 (75.1) 591 (83.4) (76.8)
‒ French or Italian 127 (24.9) 118 (16.6) <0.001 (23.2) n.a.a
Parents' highest educationf
‒ Primary education 55 (10.8) 62 (8.7) (7.3)
‒ Secondary 337 (66.0) 499 (70.4) (67.2)
‒ Tertiary 104 (20.4) 132 (18.6) (20.7)
‒ Unknown 15 (2.9) 16 (2.3) 0.375 (4.8) 0.141
Lifestyle conditions
Smoking
‒ Never 308 (62.6) 446 (63.7) (66.4)
‒ Ever 184 (37.4) 254 (36.3) 0.695 (33.6) 0.202
‒ Current 111 (22.6) 135 (19.3) 0.169 (19.5) 0.233
Body mass index (kg/m2)
‒ Underweight (<18) 26 (5.4) 16 (2.3) (2.9)
‒ Normal weight (18–24.9) 336 (69.1) 499 (71.2) (75.0)
‒ Overweight (25–30) 102 (21.0) 149 (21.3) (18.6)
‒ Obese (>30) 22 (4.5) 37 (5.3) 0.043 (3.5) 0.098
Diabetes mellitus
‒ No 500 (97.9) 706 (99.6) (99.7)
‒ Yes 11 (2.1) 3 (0.4) 0.005 (0.3) 0.002
Alcohol consumption(standard drink)
‒ Occasionally/never 198 (40.7) 233 (33.3) (28.2)
‒ ≥1 weekly, not daily 261 (53.7) 422 (60.4) (66.0)
‒ Daily 27 (5.5) 44 (6.3) 0.020 (5.8) <0.001
Physical activityg
‒ Low 163 (33.2) 209 (29.9) (26.5)
‒ Sufficient 328 (66.8) 491 (70.1) 0.221 (73.5) 0.020
ALL = acute lymphoblastic leukaemia; n.a. = not applicable; RT = radiotherapy Percentages are based upon available data for each variable a Standardised (for age, gender,
migration background and language region) numbers and percentages are given for siblings. N.A.: not applicable because this variable was used for standardisation b Column
percentages are given c P-values calculated from chi-square statistics for unweighted values comparing survivors to siblings d P-values calculated from chi-square statistics for
unweighted values comparing survivors to siblings e Migration background was defined as not born in Switzerland, no Swiss citizenship from birth or at least one parent with no
Swiss citizenship f Secondary education included high school, teacher training, vocational education and professional school; primary education involved compulsory schooling;
tertiary education included university or upper professional high school g Physical activity is defined as workout training, gym or sport (general)
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Table S2: Results from the unconditional logistic regression modela used for creating the disease risk score.
Cardiovascular disease
(n = 1122)
nb (%)c Odds ratio (95% CI)
Survivor
‒ Sibling 65 (9) 1.0
‒ Survivor 73 (14) 42.9 (5.2–353.9)
Age at questionnaire (years)
‒ 16–20 17 (7) 1.0
‒ 21–30 61 (11) 2.6 (1.3–5.4)
‒ 31–40 45 (15) 5.6 (2.6–12.4)
‒ 41 or more 15 (16) 7.9 (2.9–21.4)
Sex
‒ Male 65 (12) 1.0
‒ Female 73 (11) 0.7 (0.4–1.1)
Migration backgrounde
‒ No migration background 105 (11) 1.0
‒ Migration background 33 (15) 1.9 (1.0–3.4)
Language region
‒ German 115 (12) 1.0
‒ French or Italian 23 (9) 0.7 (0.3–1.2)
Parents' highest educationf
‒ Primary education 97 (12) 1.0
‒ Secondary 15 (13) 1.2 (0.5–2.9)
‒ Tertiary 25 (11) 1.1 (0.6–1.9)
‒ Unknown 1 (3) 6.1 (0.9–42.4)
Currently smoking
‒ No 108 (11) 1.0
‒ Yes 29 (12) 0.9 (0.4–2.0)
Ever smoked
‒ No 84 (11) 1.0
‒ Yes 53 (12) 1.0 (0.6–1.9)
Body mass index (kg/m2)
‒ Underweight (<18) 6 (14) 1.1 (0.5–2.5)
‒ Normal weight (18–24.9) 88 (11) 1.0
‒ Overweight (25–30) 28 (11) 1.1 (0.6–2.0)
‒ Obese (>30) 12 (20) 1.7 (0.7–4.0)
Diabetes
‒ No 49 (13) 1.0
‒ Yes 87 (11) 1.0 omitted d
Alcohol consumption (standard drink)
‒ Occasionally/never 59 (14) 1.0
‒ ≥1 weekly, not daily 70 (10) 1.0 (0.6–1.7)
‒ Daily 3 (6) 0.6 (0.1–2.6)
– >Daily 5 (23) 1.9 (0.6–6.2)
Physical activityg
‒ Low 49 (13) 1.0
‒ Sufficient 87 (11) 0.7 (0.4–1.3)
Year at diagnosis
Sibling 65 (9) 1.0
‒ 1976–1984 19 (14) 0.4 (0.1–1.3)
‒ 1985–1994 36 (15) 0.8 (0.3–1.8)
‒ 1995–2005 18 (14) 1.0 omitted d
Age at diagnosis
Sibling 65 (9) 1.0
‒ 0–4 29 (12) 1.0 (0.5–2.3)
‒ 5–9 21 (14) 0.7 (0.3–1.7)
‒ ≥10 23 (21) 1.0 omitted d
Relapse
‒ Sibling 65 (9) 1.0
‒ No history of relapse 56 (13) 0.6 (0.2–1.4)
‒ Relapse 17 (24) 1.0 omitted d
Chemotherapy
‒ Sibling 65 (9) 1.0
Original article Swiss Med Wkly. 2019;149:w20012
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 12 of 15
Cardiovascular disease
(n = 1122)
nb (%)c Odds ratio (95% CI)
‒ Other chemotherapy 19 (10) 0.6 (0.3–1.0)
‒ Anthracycline 54 (17) 1.0 omitted d
Radiotherapy (RT)
‒ Siblings 65 (9) 1.0
‒ No RT 48 (13) 0.7 (0.1–4.9)
‒ Other RT 21 (16) 0.7 (0.1–4.8)
‒ RT heart <20 Gy 1 (7) 0.1 (0.0–2.2)
‒ RT heart 20–39 Gy 3 (30) 1.0 omitted d
HSCT
‒ Siblings 65 (9) 1.0
‒ No HSCT 66 (14) 0.3 (0.1–1.4)
‒ HSCT 7 (29) 1.0 omitted d
Follow–up
‒ Siblings 65 (9)
‒ No follow–up 48 (14) 0.7 (0.3–1.4)
‒ Follow–up 24 (18) 1.0 omitted d
a Model adjusted for all factors shown b Absolute numbers of participants reporting to have a cardiovascular disease c Row percentages are given d Category omitted due to
collinearity or perfect prediction of outcome
Table S3: Comparison of responding and nonresponding ALL-survivors in the Swiss Childhood Cancer survivor study.
Responders
(n=511)
Nonresponders
(n=196)
p-valueb
unweighted
n (%a) n (%a)
Sociodemographic characteristics
Age at questionnaire (years) 0.043
‒ 16–20 135 (26) 69 (35)
‒ 21–30 251 (49) 74 (38)
‒ 107 (21) 45 (23)
‒ 41 or more 18 (4) 8 (4)
Gender 0.001
‒ Male 258 (50) 127 (65)
‒ Female 253 (50) 69 (35)
Language region 0.646
‒ German 384 (75) 384 (73)
‒ French or Italian 127 (25) 127 (27)
Cancer related characteristics
Age at diagnosis (years)
‒ 0–4 244 (48) 93 (47) 0.771
‒ 5–9 155 (30) 64 (33)
‒ 10 or more 112 (22) 39 (20)
Year at diagnosis 0.005
‒ 1976–1984 135 (26) 53 (27)
‒ 1985–1994 245 (48) 71 (36)
‒ 1995–2005 131 (26) 72 (37)
History of relapse 0.104
‒ No 442 (86) 160 (82)
‒ Yes 69 (14) 36 (18)
Chemotherapy n.a.
‒ Yes 511 (100) 196 (100)
Radiotherapy 0.365
‒ No 362 (71) 132 (67)
‒ Yes 149 (29) 64 (33)
HSCT 0.440
‒ No 487 (95) 184 (94)
‒ Yes 24 (5) 12 (6)
a Column percentages are given b p-values calculated from chi-squared tests comparing nonresponders to responders
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Table S4: Numbers of patients with current follow-up care among all children diagnosed with ALL, by diagnostic period.
1976–1984 1985–1995 1995–2005
No FU % a FU % No FU % FU % No FU % FU %
Sociodemographic characteristics
Age at questionnaire (years)
16–20 30 15.7 11 25.0 26 57.8 54 70.1
21–30 31 26.1 4 28.6 141 73.8 27 61.4 19 42.2 23 29.9
31–40 72 60.5 8 57.1 20 10.5 6 13.6
40 or more 16 13.4 2 14.3
Gender
Male 67 56.3 4 28.6 84 44.0 22 50.0 28 62.2 43 55.8
Female 52 43.7 10 71.4 107 56.0 22 50.0 17 37.8 34 44.2
Language region
German 94 79.0 13 92.9 144 75.4 35 79.6 27 60.0 55 71.4
French or Italian 25 21.0 1 7.1 47 24.6 9 20.5 18 40.0 22 28.6
Cancer related characteristics
Age at diagnosis (years)
0–4 59 49.6 8 57 110 57.6 21 47.7 14 31.1 21 27.3
5–9 42 35.3 6 42.9 52 27.2 13 29.6 13 28.9 22 28.6
10 or more 18 15.1 0 0.0 29 15.2 10 22.7 18 40.0 34 44.2
History of relapse
No 95 79.8 9 64.3 174 91.1 36 81.8 43 95.6 66 85.7
Yes 24 20.2 5 35.7 17 8.9 8 18.2 2 4.4 11 14.3
Chemotherapy
Yes 119 100 14 100 191 100 44 100 45 100 77 100
Radiotherapy
No 63 52.9 8 57.1 156 81.7 21` 47.7 33 73.3 66 85.7
Yes 56 47.1 6 42.9 35 18.3 23 52.3 12 26.7 11 14.3
HSCT b
No 115 96.6 11 78.6 186 97.4 40 90.9 44 97.8 72 93.5
Yes 4 3.4 3 21.4 5 2.6 4 9.1 1 2.2 5 6.5
FU = current follow-up care, HSCT = haematopoietic stem cell transplantation Percentages are based upon available data for each variable a Row percentages are given, NOTE:
Percentages are based upon available data for each variable b Includes both autologous and allogeneic, and both peripheral blood cell and bone marrow transplantation
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Table S5: Prevalence and relative odds for any cardiovascular disease without hypertension in survivors of acute lymphoblastic leukaemia compared with siblings (OR 1.0) ad-
justed for the baseline risk score.
No. total No. CVD %a CHD ORb 95% CI p-valuec
Diagnosis of ALL 511 54 10.5 2.6 1.6–4.3 0.013
Period of cancer diagnosis 0.219
1976–1984 135 14 10.3 1.7 0.7–3.7
1985–1994 245 26 10.6 2.9 1.7–5.1
1995–2005 131 14 10.7 3.9 1.9–8.1
Age at diagnosis (years) 0.431
0–4 244 24 16.7 2.7 1.5–4.9
5–9 155 14 9.0 2.0 1.0–4.0
10 or more 112 16 14.3 3.3 1.7–6.8
History of relapse 0.078
No 441 42 9.5 2.3 1.4–3.9
Yes 70 12 17.1 4.6 2.1–10.3
Chemotherapy 0.01
Other chemotherapeutic agentsd 196 13 6.6 1.3 0.6–2.9
Anthracyclines 315 41 13.0 3.5 2.1–5.9
Radiotherapy 0.910
No RT 359 35 9.7 2.5 1.5–4.3
Other RTe 128 15 11.7 2.5 1.2–5.4
Chest RTf 1–19 Gy 14 1 7.1 1.6 0.2–13.6
Chest RTf 20 or more Gy 10 3 30.0 13.5 2.5–72.6
HSCTg 0.532
No 487 51 10.5 2.6 1.5–4.2
Yes 24 3 12.5 4.0 1.0–16.5
ALL = acute lymphoblastic leukaemia; DRS = disease risk score; CVD = cardiovascular diseases; HSCT = haematopoietic stem cell transplantation; OR = odds ratio; RT = radio-
therapy; CI = confidence interval Percentages are based upon available data for each variable a Row percentages are given b Adjusted with Baseline DRS for age at questionnaire,
gender, migration background, language region, parents' education, smoking status, BMI, diabetes mellitus, alcohol consumption and physical activity c P-values calculated from
Wald test for comparison within survivors only d Other chemotherapeutic agents: any chemotherapy other than anthracycline (n = 165) and those who received chemotherapy with
unknown details (n = 31) e Other radiotherapy: no history of radiotherapy on the chest f Chest radiotherapy: mantle field, total body irradiation, thoracic spine radiation, unspecified
radiation of the thorax g Includes both autologous and allogeneic, and both peripheral blood cell and bone marrow transplantation
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